ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide

European Journal of Cancer

Volumn 35, Issue 7, 1999, Pages 1130-1135

  Pernin, D ^a   Bay, J O ^a   Uhrhammer, N ^a   Bignon, Y J ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Apoptosis; Ataxia telangiectasia; Chemosensitivity; Etoposide; Heterozygot e; Streptonigrin

Indexed keywords

ETOPOFOS; RUFOCROMOMYCIN;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER RISK; CELL FUNCTION; CELL LINE; CHEMOSENSITIVITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ATAXIA TELANGIECTASIA; CELL LINE; ETOPOSIDE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; STREPTONIGRIN;

EID: 0033166119     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00059-3     Document Type: Article

References (29)

1. Gatti R.A., Boder E., Vinters H.V., Sparkes R.S., Norman A., Lange K. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medecine. 70:1991;99-117.
2. Shiloh Y., Rotman G. Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency and cancer to cell cycle checkpoints. J. Clin. Immunol. 16:1996;254-260.
3. Savitsky K., Bar-Shira A., Gilad S.et al. A single gene with a product similar to PI-3 kinase and rad 3+ is mutated in ataxia-telangiectasia. Science. 268:1995;1749-1753.
4. Swift M., Morrel D., Massey R.B., Chase C.L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325:1991;1831-1836.
5. Easton D.F. Cancer risks in AT heterozygotes. Int. J. Radiat. Biol. 66:1994;177-182.
6. McKinnon P.J. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 55:1987;197-208.
7. Meyn M.S., Strasfeld L., Allen C. Testing the role of p53 in the expression of genetic instability in ataxia-telangiectasia. Int. J. Radiat. Biol. 66:1994;S141-S149.
8. Meyn M.S. Ataxia-telangiectasia and cellular response to DNA damage. Cancer Res. 55:1995;5991-6000.
9. 2 phase delay in ataxia telangiectasia heterozygotes. Cancer Genet. Cytogenet. 60:1992;183-187.
10. Taylor A.M.R., Byrd P.J., McConville C.M., Thacker S. Genetic and cellular features of ataxia telangiectasia. Int. J. Radiat. Biol. 65:1994;65-70.
11. Birrell G.W., Ramsay J.R. Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. Br. J. Cancer. 72:1995;1096-1101.
12. 2 phase chromosomal radiosensitivity of peripheral blood lymphocytes. Hum. Genet. 101:1997;312-316.
13. Appleby J.M., Barber J.B., Levine E.et al. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br. J. Cancer. 76:1997;1546-1549.
14. Gavrieli Y., Sherman Y., Ben-Sasson S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:1992;493-501.
15. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
16. Long B.H. Mechanisms of action of tinoposide (VM-26) and comparison with etoposide (VP-16). Semin. Oncol. 19:1992;3-19.
17. Cohen M.M., Shaw M.W., Craig A.P. The effect of streptonigrin on cultured human leukocytes. Proc. Natl. Acad. Sci. USA. 50:1963;16-24.
18. Mizuno N.S. Comparative effect of streptonigrin derivatives on tissue culture cells. Biochem. Pharmacol. 16:1967;933-940.
19. Weeks D.E., Paterson M.C., Lange K.et al. Assessment of chronic gamma radiosensitivity as in vitro assay for heterozygote identification of ataxia-telangiectasia. Radiat. Res. 128:1991;90-99.
20. Morgan J.L., Holcomb T.M., Morrissey R.W. Radiation reaction in ataxia telangiectasia. Am. J. Dis. Child. 116:1968;557-558.
21. McConville C., Stankovic T., Byrd P.J.et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am. J. Hum. Genet. 59:1996;320-330.
22. Telatar M., Wang Z., Udar N.et al. Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am. J. Hum. Genet. 59:1996;40-44.
23. Telatar M., Wang Z., Udar N.et al. Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am. J. Hum. Genet. 62:1998;86-97.
24. Morgan S.E., Lovly C., Pandita T.K., Shiloh Y., Kastan M.B. Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 17:1997;2020-2029.
25. Lakin N.D., Weber P., Stankovic T., Rottinghaus S.T., Taylor A.M.R., Jackson S.P. Analysis of the ATM protein in wild-type and ataxia-telangiectasia cells. Oncogene. 13:1996;2707-2716.
26. Gilad S., Chessa L., Khosravi R.et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am. J. Hum. Genet. 62:1998;551-561.
27. 0) T-lymphocytes, T-lymphocyte lines, lymphoblastoïd cell lines and fibroblasts from normal donor, from ataxia-telangiectasia patients and from ataxia-telangiectasia heterozygotes. Int. J. Radiat. Biol. 54:1988;929-943.
28. Jasper N.G.J., de Wit J., Regulski M.R., Bootsma D. Abnormal regulation of DNA replication and increased lethality in ataxia telangiectasia cells exposed to carcinogenic agents. Cancer Res. 42:1982;335-341.
29. Jongmans W., Vuillaume M., Chrzanowska K., Smeets D., Sperling K., Hall J. Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Mol. Cell. Biol. 17:1997;5016-5022.